These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
117 related items for PubMed ID: 23656470
1. Enteric-coated alendronate sodium nanoliposomes: a novel formula to overcome barriers for the treatment of osteoporosis. Hosny KM, Ahmed OA, Al-Abdali RT. Expert Opin Drug Deliv; 2013 Jun; 10(6):741-6. PubMed ID: 23656470 [Abstract] [Full Text] [Related]
2. Alendronate Sodium as Enteric Coated Solid Lipid Nanoparticles; Preparation, Optimization, and In Vivo Evaluation to Enhance Its Oral Bioavailability. Hosny KM. PLoS One; 2016 Jun; 11(5):e0154926. PubMed ID: 27148747 [Abstract] [Full Text] [Related]
3. Improved oral bioavailability of alendronate via the mucoadhesive liposomal delivery system. Han HK, Shin HJ, Ha DH. Eur J Pharm Sci; 2012 Aug 15; 46(5):500-7. PubMed ID: 22522117 [Abstract] [Full Text] [Related]
4. The absorption of (99m)Tc-alendronate given by rectal route in rabbits. Asikoğlu M, Ozguney I, Ozcan I, Orumlu O, Guneri T, Koseoğlu K, Ozkilic H. Pharm Dev Technol; 2008 Aug 15; 13(3):213-20. PubMed ID: 18484490 [Abstract] [Full Text] [Related]
5. Development of a novel self-dissolving microneedle array of alendronate, a nitrogen-containing bisphosphonate: evaluation of transdermal absorption, safety, and pharmacological effects after application in rats. Katsumi H, Liu S, Tanaka Y, Hitomi K, Hayashi R, Hirai Y, Kusamori K, Quan YS, Kamiyama F, Sakane T, Yamamoto A. J Pharm Sci; 2012 Sep 15; 101(9):3230-8. PubMed ID: 22467424 [Abstract] [Full Text] [Related]
6. Gastroresistant microparticles containing sodium alendronate prevent the bone loss in ovariectomized rats. Cruz L, Assumpção E, Andrade SF, Conrado DJ, Kulkamp IC, Guterres SS, Pohlmann AR. Eur J Pharm Sci; 2010 Aug 11; 40(5):441-7. PubMed ID: 20471479 [Abstract] [Full Text] [Related]
7. Encapsulation into PEG-liposomes does not improve the bioavailability of pulmonary delivered salmon calcitonin. Swaminathan J, Gobbo OL, Tewes F, Healy AM, Ehrhardt C. J Aerosol Med Pulm Drug Deliv; 2014 Feb 11; 27(1):1-11. PubMed ID: 24252061 [Abstract] [Full Text] [Related]
8. Quality by design approach to optimize the formulation variables influencing the characteristics of biodegradable intramuscular in-situ gel loaded with alendronate sodium for osteoporosis. Hosny KM, Rizg WY. PLoS One; 2018 Feb 11; 13(6):e0197540. PubMed ID: 29856752 [Abstract] [Full Text] [Related]
9. Ultrasound-assisted transdermal delivery of alendronate for the treatment of osteoporosis. Li B, Huang G, Ma Z, Qin S. Acta Biochim Pol; 2020 Jun 19; 67(2):173-179. PubMed ID: 32558528 [Abstract] [Full Text] [Related]
10. Positively-charged microemulsion for improving the oral bioavailability of alendronate: in-vitro and in-vivo assessment. Meng J, Hu L. J Pharm Pharmacol; 2011 Mar 19; 63(3):400-8. PubMed ID: 21749388 [Abstract] [Full Text] [Related]
11. Duodenum-triggered delivery of pravastatin sodium via enteric surface-coated nanovesicular spanlastic dispersions: development, characterization and pharmacokinetic assessments. Tayel SA, El-Nabarawi MA, Tadros MI, Abd-Elsalam WH. Int J Pharm; 2015 Apr 10; 483(1-2):77-88. PubMed ID: 25666025 [Abstract] [Full Text] [Related]
12. pH-dependent release of platycodin mitigates its gastrointestinal mucosa irritation after oral administration in rats. Chen Q, Yang WW, Shen P, Cao QR, Lee BJ, Cui JH. Arch Pharm Res; 2016 Jun 10; 39(6):811-24. PubMed ID: 27241507 [Abstract] [Full Text] [Related]
13. Studies on the formation of hydrophobic ion-pairing complex of alendronate. You SK, Kwon HH, Lee JM, Shin SC, Cho CW. Arch Pharm Res; 2009 Jul 10; 32(7):1055-60. PubMed ID: 19641887 [Abstract] [Full Text] [Related]
14. Alendronate-loaded microparticles for improvement of intestinal cellular absorption. Baek JS, Kwon HH, Hwang JS, Sung HC, Lee JM, Shin SC, Kim YR, Cho CW. J Drug Target; 2011 Jan 10; 19(1):37-48. PubMed ID: 20477555 [Abstract] [Full Text] [Related]
15. A trial for the design and optimization of pH-sensitive microparticles for intestinal delivery of cinnarizine. Ammar HO, Ghorab M, Kamel R, Salama AH. Drug Deliv Transl Res; 2016 Jun 10; 6(3):195-209. PubMed ID: 26747332 [Abstract] [Full Text] [Related]
16. Eudraginated polymer blends: a potential oral controlled drug delivery system for theophylline. Emeje M, John-Africa L, Isimi Y, Kunle O, Ofoefule S. Acta Pharm; 2012 Mar 10; 62(1):71-82. PubMed ID: 22472450 [Abstract] [Full Text] [Related]
17. Preparation and Evaluation of Enteric-Coated Chitosan Derivative-Based Microparticles Loaded with Salmon Calcitonin as an Oral Delivery System. Onishi H, Tokuyasu A. Int J Mol Sci; 2016 Sep 13; 17(9):. PubMed ID: 27649146 [Abstract] [Full Text] [Related]
18. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers. Rhim SY, Park JH, Park YS, Lee MH, Kim DS, Shaw LM, Yang SC, Kang JS. Clin Ther; 2009 May 13; 31(5):1037-45. PubMed ID: 19539104 [Abstract] [Full Text] [Related]
19. Development of enteric-coated fixed dose combinations of amorphous solid dispersions of ezetimibe and lovastatin: Investigation of formulation and process parameters. Riekes MK, Dereymaker A, Berben P, Augustijns P, Stulzer HK, Van den Mooter G. Int J Pharm; 2017 Mar 30; 520(1-2):49-58. PubMed ID: 28153650 [Abstract] [Full Text] [Related]
20. Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery. Akhgari A, Afrasiabi Garekani H, Sadeghi F, Azimaie M. Int J Pharm; 2005 Nov 23; 305(1-2):22-30. PubMed ID: 16236475 [Abstract] [Full Text] [Related] Page: [Next] [New Search]